NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.40+0.17 (+2.73%)
Close on Nov 13, 2026Market cap $29.30MP/E –Yield 0.00%
NextCure total assets
Total assets on the balance sheet at the end of each period.
NextCure's total assets was $22.62M at Jun 30, 2026. For fiscal 2025 it was $50.18M, down 37.9% from the year before. The highest annual figure on record is $356.17M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.18M | -37.9% |
| FY2024 | Dec 31, 2024 | $80.86M | -36.8% |
| FY2023 | Dec 31, 2023 | $128.04M | -30.5% |
| FY2022 | Dec 31, 2022 | $184.16M | -24.0% |
| FY2021 | Dec 31, 2021 | $242.39M | -21.0% |
| FY2020 | Dec 31, 2020 | $306.64M | -13.9% |
| FY2019 | Dec 31, 2019 | $356.17M | +141.3% |
| FY2018 | Dec 31, 2018 | $147.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.62M | -52.6% |
| Q1 FY2026 | Mar 31, 2026 | $37.98M | -43.4% |
| Q4 FY2025 | Dec 31, 2025 | $50.18M | -37.9% |
| Q3 FY2025 | Sep 30, 2025 | $39.61M | -56.2% |
| Q2 FY2025 | Jun 30, 2025 | $47.69M | -53.5% |
| Q1 FY2025 | Mar 31, 2025 | $67.14M | -41.7% |
| Q4 FY2024 | Dec 31, 2024 | $80.86M | -36.8% |
| Q3 FY2024 | Sep 30, 2024 | $90.35M | -35.4% |
| Q2 FY2024 | Jun 30, 2024 | $102.59M | -33.1% |
| Q1 FY2024 | Mar 31, 2024 | $115.16M | -31.4% |
| Q4 FY2023 | Dec 31, 2023 | $128.04M | -30.5% |
| Q3 FY2023 | Sep 30, 2023 | $139.94M | -26.3% |
| Q2 FY2023 | Jun 30, 2023 | $153.38M | -25.7% |
| Q1 FY2023 | Mar 31, 2023 | $167.79M | -24.7% |
| Q4 FY2022 | Dec 31, 2022 | $184.16M | -24.0% |
| Q3 FY2022 | Sep 30, 2022 | $189.91M | -26.3% |
| Q2 FY2022 | Jun 30, 2022 | $206.37M | -25.1% |
| Q1 FY2022 | Mar 31, 2022 | $222.75M | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $242.39M | -21.0% |
| Q3 FY2021 | Sep 30, 2021 | $257.83M | -18.4% |
| Q2 FY2021 | Jun 30, 2021 | $275.36M | -17.4% |
| Q1 FY2021 | Mar 31, 2021 | $290.96M | -15.3% |
| Q4 FY2020 | Dec 31, 2020 | $306.64M | -13.9% |
| Q3 FY2020 | Sep 30, 2020 | $316.08M | +54.1% |
| Q2 FY2020 | Jun 30, 2020 | $333.49M | +56.5% |
| Q1 FY2020 | Mar 31, 2020 | $343.47M | +136.2% |
| Q4 FY2019 | Dec 31, 2019 | $356.17M | +141.3% |
| Q3 FY2019 | Sep 30, 2019 | $205.12M | – |
| Q2 FY2019 | Jun 30, 2019 | $213.05M | – |
| Q1 FY2019 | Mar 31, 2019 | $145.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $147.63M | – |
See a number that looks wrong?